Kewaunee Scientific Corporation (NasdaqGM:KEQU) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Kewaunee Scientific Corporation to reach your target.
Based on historical returns, we believe that Kewaunee Scientific Corporation can grow its free cash at a rate of about 3%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| KEQU Price (Kewaunee Scientific Corporation stock price per share) |
$34.66 | |
|
|
KEQU Fair Price (based on intrinsic value) |
$25.81 |
| KEQU Safety Price (based on a variable margin of safety) | $15.49 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 23% lower than other Technology stocks | |
| PE Ratio versus Industry | 58% lower than other Scientific & Technical Instruments stocks | |
| Free Cash Flow Jitter | 256% | |
No open-market insider buys or sells are recorded for the last 12 months.
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 38,286 shares shorted. With 2,156,483 shares available for purchase and an average trading volume over the past 10 trading days of 4,660, it would take at least 8.2 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2010 | 55529 | 0.3 |
| 2011 | 55529 | -3.5 |
| 2012 | 55529 | 3.3 |
| 2013 | 55529 | 0.5 |
| 2014 | 55529 | 5 |
| 2015 | 55529 | -0.4 |
| 2016 | 55529 | 5.1 |
| 2017 | 55529 | 9.3 |
| 2018 | 55529 | 0.6 |
| 2019 | 55529 | -0.5 |
| 2020 | 55529 | 1.2 |
| 2021 | 55529 | -2.1 |
| 2022 | 55529 | -10.8 |
| 2023 | 55529 | -6.8 |
| 2024 | 55529 | 16.5 |
| 2025 | 55529 | 11.8 |
| 2026 | 55529 | 15.3 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 14 fiscal years from 2010 to 2026 with positive net income, operating cash flow totaled $101 million against net income of $72.6 million, or 1.39 times. Net income was negative in 3 of the 17 years, and those years are left out of the ratio.
In 2026, operating cash flow was 1.94 times net income, compared with 1.97 times for the earliest three years (2010 to 2012).
In 2026, capital expenditures were $3.9 million, 21.1% of operating cash flow of $18.6 million, which leaves an estimated $14.7 million after capex. Across the 15 years with reported capex, it averaged 41.7% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2010 | 3.6 | 4.5 | 4.2 | 1.27 |
| 2011 | 1.9 | 1.3 | 5.2 | 0.69 |
| 2012 | 1 | 6.9 | 1.4 | 6.71 |
| 2013 | 3 | 3.8 | 2.4 | 1.26 |
| 2014 | 3.9 | 8.1 | 2 | 2.07 |
| 2015 | 3.5 | 2.3 | 2.6 | 0.65 |
| 2016 | 3.8 | 7.3 | 2.2 | 1.91 |
| 2017 | 4.5 | 11.7 | 2.6 | 2.58 |
| 2018 | 5.3 | 3.2 | 3.4 | 0.60 |
| 2019 | 1.5 | 2.5 | 4.2 | 1.63 |
| 2020 | -4.7 | 4.2 | 2.5 | n/a |
| 2021 | -3.7 | 0.9 | 2.4 | n/a |
| 2022 | -6.1 | -7.9 | 1.9 | n/a |
| 2023 | 0.7 | -3.8 | 4.1 | -5.14 |
| 2024 | 18.8 | 19.6 | 4.4 | 1.04 |
| 2025 | 11.4 | 14.8 | 2.2 | 1.30 |
| 2026 | 9.6 | 18.6 | 3.9 | 1.94 |
How to read this: why companies buy back shares, dividend yield explained.
Over the 10 fiscal years from 2013 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $49.1 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In the 8 of those years with dividend payment facts, dividends paid totaled $11.2 million, 53.8% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 4 of those 8 years.
In 2 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $3.6 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2025, cash spent repurchasing shares was $1.6 million, 13.5% of estimated free cash flow of $11.8 million.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2013 | 0.5 | 1 | n/a | 1 | 208.9% |
| 2014 | 5 | 1.1 | n/a | 1.1 | 22.4% |
| 2015 | -0.4 | 1.2 | n/a | 1.2 | n/a |
| 2016 | 5.1 | 1.4 | n/a | 1.4 | 26.4% |
| 2017 | 9.3 | 1.6 | n/a | 1.6 | 16.9% |
| 2018 | 0.6 | 1.8 | n/a | 1.8 | 286.3% |
| 2019 | -0.5 | 2 | n/a | 2 | n/a |
| 2020 | 1.2 | 1 | n/a | 1 | 88.0% |
| 2024 | 16.5 | n/a | 2 | 2 | 12.1% |
| 2025 | 11.8 | n/a | 1.6 | 1.6 | 13.5% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $99.1 million in 2010 and $282 million in 2026, a compound annual growth rate of 6.8% over 16 years.
Revenue rose 17.3% from 2025 to 2026.
Our estimated free cash flow was $15.3 million in 2026, 5.4% of revenue. In 2010 the estimated margin was 0.3%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2010 | 99.1 | 0.3 | 0.3% |
| 2011 | 100 | -3.5 | -3.5% |
| 2012 | 103 | 3.3 | 3.2% |
| 2013 | 117 | 0.5 | 0.4% |
| 2014 | 111 | 5 | 4.5% |
| 2015 | 119 | -0.4 | -0.4% |
| 2016 | 129 | 5.1 | 4.0% |
| 2017 | 139 | 9.3 | 6.7% |
| 2018 | 158 | 0.6 | 0.4% |
| 2019 | 147 | -0.5 | -0.3% |
| 2020 | 148 | 1.2 | 0.8% |
| 2021 | 147 | -2.1 | -1.4% |
| 2022 | 169 | -10.8 | -6.4% |
| 2023 | 219 | -6.8 | -3.1% |
| 2024 | 204 | 16.5 | 8.1% |
| 2025 | 240 | 11.8 | 4.9% |
| 2026 | 282 | 15.3 | 5.4% |
How to read this: how debt and assets are compared, the current ratio.
In 2026, cash and equivalents were $9.9 million against total liabilities of $101 million, or 9.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 56.9% of total assets in 2026, compared with 47.6% in 2011, an increase of 9.3 percentage points.
Stockholders equity was $76.8 million in 2026, compared with $33 million in 2011, a rise of 132.7%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 12.8% in 2026. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2011 | 63.1 | 2.4 | 30 | 33 |
| 2012 | 63.4 | 6.2 | 31.7 | 31.7 |
| 2013 | 68.7 | 5.8 | 35 | 33.7 |
| 2014 | 62.7 | 6.2 | 28.5 | 34.2 |
| 2015 | 69.5 | 3 | 34.3 | 35.2 |
| 2016 | 72.4 | 5.2 | 33.9 | 38.6 |
| 2017 | 80.9 | 12.5 | 37.7 | 43.8 |
| 2018 | 85.1 | 9.7 | 36.9 | 48.2 |
| 2019 | 87.2 | 10.6 | 39.5 | 47.7 |
| 2020 | 83.9 | 4.4 | 45.2 | 38.7 |
| 2021 | 89.4 | 5.2 | 47.9 | 41.5 |
| 2022 | 119 | 4.4 | 82.6 | 36.2 |
| 2023 | 119 | 8.1 | 80.4 | 38.5 |
| 2024 | 135 | 23.3 | 78.6 | 56.2 |
| 2025 | 195 | 14.9 | 128 | 66.2 |
| 2026 | 178 | 9.9 | 101 | 76.8 |
At $34.66, Kewaunee Scientific Corporation trades above our fair value estimate of $25.81.
Only 11 of the 17 fiscal years under Kewaunee Scientific Corporation's current filer show positive free cash flow.
Comparing the first and last three years of data, average free cash flow rose sharply: $0 million at the start and $14.5 million most recently.
Free cash flow is volatile from year to year, with a variability measure of 256%.
Our value investing guide explains how to test these numbers against the filings themselves.
Dividends are not in our data for Kewaunee Scientific Corporation.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 23% below the average for stocks in the Technology sector.
Its trailing P/E ratio is 58% below the average for stocks in the Scientific & Technical Instruments industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Scientific & Technical Instruments industry, the ones closest in market capitalization to Kewaunee Scientific Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Kewaunee Scientific Corporation (KEQU) | 100 | 12.6 | - | - | 34% above |
| Mesa Laboratories (MLAB) | 775 | 118.8 | 0.5% | 1.4% | 76% above |
| Transcat (TRNS) | 937 | 207.6 | - | - | 212% above |
| Itron (ITRI) | 4,298 | 15.9 | - | 4.4% | 8% below |
| Sensata Technologies Holding plc (ST) | 5,464 | 15.0 | 1.3% | 11.8% | 59% below |
| Cognex Corporation (CGNX) | 8,272 | 34.4 | 0.7% | 1.3% | 117% above |
| Bio-Rad Laboratories (BIO) | 9,633 | 9.5 | - | 0.8% | 9% below |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 55529.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: KEQU annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Kewaunee Scientific Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to KEQU: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is Dollar Cost Averaging?
Benjamin Graham, Value Investor
How Do Tariffs Affect the Stock Market?
Precious Metals for Value Investors